We recently published a list of 20 Most Expensive Stocks Insiders Are Dumping In March. In this article, we are going to take ...

Madrigal (MDGL) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

In a report released today, Jason Zemansky from Bank of America Securities reiterated a Buy rating on Acumen Pharmaceuticals (ABOS – Research ...

Detailed price information for Nektar Therapeutics (NKTR-Q) from The Globe and Mail including charting and trades.

Discover why Gyre Therapeutics is rated 'Hold' amid volatile stock behavior, uncertain long-term prospects, and pending Phase ...

A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...

Detailed price information for Lenz Therapeutics Inc (LENZ-Q) from The Globe and Mail including charting and trades.

We recently compiled a list of the 15 Best Biotech Stocks to Buy According to Billionaires. In this article, we are going to ...

CONSHOHOCKEN, PA — Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) has announced the appointment of Jacqualyn (“Jackie”) Fouse, Ph.D., to its Board of Directors, bringing decades of leadership and ...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has been making waves in the biopharmaceutical industry with its flagship product, Rezdiffra, a treatment for non-alcoholic steatohepatitis (NASH).

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...